Auriga

Auriga reiterates its Buy rating and $95 target price on McKesson NYSE: MCK) on share buyback, acquisition activity, and a strong quarter where results outpaced consensus estimates. Auriga says, "McKesson's portfolio approach to capital deployment was evidenced in the quarter as it: 1) announced...

Auriga reiterates its Buy rating and $17 price target on Globe Specialty Metals (NASDAQ: GSM) on improving demand trends. Auriga notes, "We note the near-term demand commentary is consistent with what we are hearing from many of the management teams of other companies we follow. While the broader...

Auriga reiterates its Buy rating on Marvel Technology (NASDAQ: MRVL) and raises its target price by $1 to $18 on increased share multiple. Auriga notes, "We maintain our Buy Rating and increase our price target to $18 from $17 for Marvell (MRVL) on a higher multiple of FY13 EPS. The company...

Auriga has raised the price target on Marvell Technology Group (NYSE: MRVL) from $17 to $18 and maintains its Buy rating.

Auriga lowers its rating on Juniper (NASDAQ: JNPR) to Hold from Buy and cuts its price target to $23 from $26 as company's guidance falls short of expectations again. Auriga notes, "The company's 1Q12 guidance fell significantly short of our/consensus estimate on cautious service provider trends...

Auriga has downgraded Juniper Networks (NASDAQ: JNPR) from Buy to Hold and has lowered the price target from $26 to $23.

Auriga has lowered the price target on Riverbed Technology (NASDAQ: RVBD) from $29 to $26 and maintains its Hold rating.

Auriga has published a research report on HCA Holdings (NYSE: HCA) and has downgraded the company from Buy to Hold. In the report, Auriga writes, "In a nutshell we believe the macro issues HCA and the other hospital companies have faced have moderated but not disappeared and will remain on the...

Auriga has downgraded HCA Holdings (NYSE: HCA) from Buy to Hold and maintains its $28 price target.

Auriga reiterates its Buy rating and $95 target price on Waters (NYSE: WAT) as the company posts solid results in 4Q and an outlook that likely is conservative into 2012. Auriga says, "Waters reported 4Q11 revenues of $521MM (+8%; 8% org, 0% F/X) and non-GAAP EPS of $1.56 (+13% Y/Y), with both...

Auriga maintains its Hold rating on Altera (NASDAQ: ALTR) but raises its price target to $38 from $36 as it believes a surprisingly low guidance from the company signals a bottom. Auriga says, "ALTR called 1Q12 a bottom and expects revenue to grow in 2Q12. We agree with the company's assessment...

Auriga reiterates its Sell rating and $18 target price on Fusion-IO (NYSE: FIO) as the company dissapointed in earnings outlook, despite a strong revenue quarter. Auriga says, "We reiterate a SELL rating following a mixed earnings release that showed continued strong sales growth, but with a...

Auriga reiterates its Buy rating on Apple (NASDAQ: AAPL) and raises its price target by $100 to $650 on a stellar quarter. Auriga says, "Apple posted blow-out F1Q12 results, driven primarily by the iPhone, but just about all other product areas contributed upside as well. We continue to believe...

Auriga maintains its Buy rating and $56 target price on Crane (NYSE: CR) despite a fourth quarter miss of $0.02, which Auriga says is driven by expected accounting events. Auriga notes, "In tandem with fourth-quarter results, the company extended its asbestos liability to 2021, from 2017...

Auriga maintains its Buy rating and price target of $17 on NutriSystem (NASDAQ: NTRI) as it sees entry opportunity in the company shares' recent pullback, which is potentially driven on lack of promotion. Auriga says, "Investors Should Not Panic Over Limited Nutrisystem Promotion. While we are...